Ide Masayuki, Yamada Kazuo, Toyota Tomoko, Iwayama Yoshimi, Ishitsuka Yuichi, Minabe Yoshio, Nakamura Kazuhiko, Hattori Nobutaka, Asada Takashi, Mizuno Yoshikuni, Mori Norio, Yoshikawa Takeo
Laboratory for Molecular Psychiatry, RIKEN Brain Science Institute, 2-1 Hirosawa, Wako-city, Saitama 351-0198, Japan.
Hum Genet. 2005 Oct;117(6):520-7. doi: 10.1007/s00439-005-1342-8. Epub 2005 Jul 14.
We previously identified frequent deletion/insertion polymorphisms in the 20-alanine homopolymer stretch of PHOX2B (PMX2B), the gene for a transcription factor that plays important roles in the development of oculomotor nerves and catecholaminergic neurons and regulates the expression of both tyrosine hydroxylase and dopamine beta-hydroxylase genes. An association was detected between gene polymorphisms and overall schizophrenia, and more specifically, schizophrenia with ocular misalignment. These prior results implied the existence of other schizophrenia susceptibility genes that interact with PHOX2B to increase risk of the combined phenotype. ASCL1 was considered as a candidate interacting partner of PHOX2B, as ASCL1 is a transcription factor that co-regulates catecholamine-synthesizing enzymes with PHOX2B. The genetic contributions of PHOX2B and ASCL1 were examined separately, along with epistatic interactions with broader candidate phenotypes. These phenotypes included not only schizophrenia, but also bipolar affective disorder and Parkinson's disease (PD), each of which involve catecholaminergic function. The current case-control analyses detected nominal associations between polyglutamine length variations in ASCL1 and PD (P=0.018), but supported neither the previously observed weak association between PHOX2B and general schizophrenia, nor other gene-disease correlations. Logistic regression analysis revealed the effect of ASCL1 dominant x PHOX2B additive (P=0.008) as an epistatic gene-gene interaction increasing risk of PD. ASCL1 controls development of the locus coeruleus (LC), and accumulating evidence suggests that the LC confers protective effects against the dopaminergic neurodegeneration inherent in PD. The present genetic data may thus suggest that polyglutamine length polymorphisms in ASCL1 could influence predispositions to PD through the fine-tuning of LC integrity.
我们之前在PHOX2B(PMX2B)基因的20个丙氨酸同聚物延伸区域中鉴定出频繁的缺失/插入多态性,该基因是一种转录因子,在动眼神经和儿茶酚胺能神经元的发育中起重要作用,并调节酪氨酸羟化酶和多巴胺β-羟化酶基因的表达。我们检测到基因多态性与精神分裂症总体之间存在关联,更具体地说,与眼球排列不齐的精神分裂症存在关联。这些先前的结果表明,存在其他精神分裂症易感基因,它们与PHOX2B相互作用,增加了合并表型的风险。ASCL1被认为是PHOX2B的候选相互作用伙伴,因为ASCL1是一种转录因子,与PHOX2B共同调节儿茶酚胺合成酶。我们分别研究了PHOX2B和ASCL1的遗传贡献,以及与更广泛候选表型的上位性相互作用。这些表型不仅包括精神分裂症,还包括双相情感障碍和帕金森病(PD),每一种都涉及儿茶酚胺能功能。当前的病例对照分析检测到ASCL1中多聚谷氨酰胺长度变异与PD之间存在名义上的关联(P = 0.018),但既不支持先前观察到的PHOX2B与一般精神分裂症之间的微弱关联,也不支持其他基因与疾病的相关性。逻辑回归分析揭示了ASCL1显性×PHOX2B加性(P = 0.008)作为一种上位性基因-基因相互作用增加了PD风险。ASCL1控制蓝斑(LC)的发育,越来越多的证据表明,LC对PD固有的多巴胺能神经退行性变具有保护作用。因此,目前的遗传数据可能表明,ASCL1中的多聚谷氨酰胺长度多态性可能通过微调LC完整性来影响PD的易感性。